India, Sept. 28 -- Lifecore Biomedical, Inc. (LFCR) has agreed to be acquired by Webster Equity Partners in a transaction valued at up to $663.7 million, providing shareholders with immediate cash consideration and the potential for additional payments tied to future business performance.
Lifecore is a contract development and manufacturing organization (CDMO) that develops and manufactures complex injectable pharmaceuticals products and supplies pharmaceutical-grade hyaluronic acid for medical applications.
Under the terms of the agreement, an affiliate of Webster Equity Partners will acquire all outstanding Lifecore common stock for $6.28 per share in cash, plus one non-tradable contingent value right (CVR) per share. The CVRs could pro...